- THERMAC trial reports a 94% efficacy rate with zero complications for IceCure's ProSense® cryoablation system.
- Prof. Vogl's study shows a 2.9-year mean progression-free survival for patients treated with ProSense®.
- Combination of cryoablation and hormonal therapy results in a 94% tumor size reduction.
IceCure Medical Ltd. (ICCM, Financial) showcased its ProSense® cryoablation system at the European Conference on Interventional Oncology (ECIO) 2025 in Rotterdam, emphasizing its effectiveness in breast cancer treatment. The ProSense® system, which destroys tumors by freezing, was featured in several studies, underlining its potential as a minimally invasive alternative to traditional surgery.
The THERMAC trial reported impressive results, achieving a 94% efficacy rate and having zero complications. Significantly, 95% of the patients preferred cryoablation over traditional surgical methods. These results highlight ProSense®'s promise as a patient-friendly option that aligns with modern patient-centered care models.
A study led by Prof. Vogl further established ProSense®'s clinical value, showing a mean progression-free survival of 2.9 years in patients with primary breast cancer. This finding is pivotal, as it underscores the treatment's durability and potential in managing breast tumors non-surgically.
Moreover, a comparative study demonstrated that combining cryoablation with hormonal therapy led to a 94% reduction in tumor size. This superior outcome compared to standalone therapies illustrates the potential synergistic effects of integrating cryoablation with hormonal treatments.
The ECIO 2025 conference also facilitated hands-on training and expert sessions, reflecting a growing interest in ProSense® across European markets. This increased attention indicates potential for ProSense®'s continued adoption and integration into clinical practice, particularly for patients ineligible for surgery.
